Infection nosocomiale à Staphylococcus aureus résistant à la méthicilline chez un patient adulte hospitalisé : quel antibiotique choisir ?
Bibliographic record
Abstract
Resume Objectifs : Le programme de gestion therapeutique des medicaments a revu la documentation scientifique afin d’emettre des recommandations permettant de positionner, sur une liste locale de medicaments, les antibiotiques utilises pour traiter l’infection nosocomiale a Staphylococcus aureus resistant a la methicilline du patient adulte hospitalise. Source des donnees et selection des etudes : Revue de litterature effectuee sur Pubmed et Embase afin de selectionner les meta-analyses, etudes cliniques et lignes directrices pertinentes. Une critique objective des selections a ete faite pour en evaluer la qualite. D’autres sources specialisees ont ete consultees. Analyse des donnees : Dans la majorite des etudes, les resultats associes au Staphylococcus aureus resistant a la methicilline proviennent d’analyses de sous-groupes, dont le protocole de recherche n’etait pas concu pour evaluer cette population. On rapporte generalement un nombre insuffisant de patients pour atteindre une puissance statistique permettant de preciser l’efficacite contre le Staphylococcus aureus resistant a la methicilline par rapport aux traitements standards. Beaucoup de biais methodologiques sont presents, ce qui limite la validite des conclusions des auteurs des etudes. Conclusion : La vancomycine demeure encore le traitement de premiere intention des infections causees par le Staphylococcus aureus resistant a la methicilline, aucune superiorite n’ayant pu etre clairement demontree avec tout autre antibiotique. Pour un traitement prouve ou empirique d’une infection a Staphylococcus aureus resistant a la methicilline, le programme de gestion therapeutique des medicaments recommande de positionner les autres molecules en deuxieme intention, lorsque la vancomycine ne peut etre utilisee. Le linezolide fait exception, car de recentes donnees permettent de le recommander en premiere intention de traitement de la pneumonie nosocomiale a Staphylococcus aureus resistant a la methicilline, au meme titre que la vancomycine. Abstract Objective: To evaluate the The Therapeutic Drug Management Program (TDMP) reviewed the scientific literature to provide recommendations on the antibiotics used to treat methicillin-resistant Staphylococcus aureus (MRSA) infections in hospitalized adult patients. Data sources and study selection: A literature review was done using PubMed and Embase to select meta-analyses, clinical studies, and relevant guidelines both in English and French language. Other specialized data sources were also consulted. An objective critical appraisal of the quality of these selections was done. Data analysis: In most studies, results related to MRSA came from sub-group analyses where the protocol was not intended to evaluate this study population. An insufficient number of patients to reach statistical power to determine efficacy against MRSA in relation to standard treatments is generally reported. A number of methodological biases are present, limiting the validity of the conclusions drawn by the authors of the studies. Conclusion: Vancomycin still remains the first line treatment against MRSA infections, as superiority has not been demonstrated with any other antibiotic. Whether for empiric or proven treatment of an MRSA infection, the TDMP recommends to rank the other drugs as second line when vancomycin cannot be used. Linezolid is an exception in that recent data has shown that it can be recommended, like vancomycin, as first line treatment for hospital acquired pneumonia due to MRSA. Key words: Daptomycin, linezolid, methicillin-resistant Staphylococcus aureus , tigecycline
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.025 | 0.087 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.003 | 0.002 |
| Bibliometrics | 0.002 | 0.003 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.004 | 0.003 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".